Anna Oleárová

Dr. Anna Oleárová

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2020 in Klinická farmakologie a farmacie
Verified
Journal Article
Open access
PDF file
AOAnna Oleárová
Anna Oleárová
Hyperaktívny močový mechúr je častým problémom starších pacientov. Vo farmakoterapii sa najčastejšie používajú anticholinergiká

11 November 2024 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
YJYashar Jalali
Yashar Jalali
AKAndrea Kološová
Andrea Kološová
Adriána LiptákováAdriána Liptáková
Adriána Liptáková
JKJan Kyselovic
Jan Kyselovic
AOAnna Oleárová
Anna Oleárová
JPJuraj Payer
Juraj Payer
Background/Objectives: Over the past few decades, extended-spectrum β-lactamase (ESBL)-producing bacteria have become a great concern in healthcare systems worldwide, imposing large burdens by increasing antimicrobial resistance and patient morbidity. Given the high mortality rates and emergence of multidrug-resistant (MDR) strains, monitoring ESBL prevalence and resistance patterns is crucial. This study aimed to evaluate ESBL-producing Escherichia coli, Proteus mirabilis, and Klebsiella pneumoniae over three years, focusing on phenotypic distribution and resistance profiles. Methods: A total of 1599 ESBL-producing bacterial samples were collected and analysed. A panel of 20 antibiotics was tested to determine resistance traits. Data were recorded on phenotypical distribution, isolation types, changes in antibiotic resistance, and the relation of such changes to antibiotic consumption (defined daily dose) from clinical isolates. Results: Phenotypical analysis revealed the minimal presence of the Cefotaximase from Munich (CTX-M) phenotype in E. coli and K. pneumoniae, creating a distinct epidemiological profile compared to global patterns. Shifts in isolation trends, particularly in P. mirabilis, suggest an expected increase in associated-mortality-rate in the coming years. While resistance trends were not statistically significant, MDR and extensively drug-resistant (XDR) strains were identified across all three bacteria. Only meropenem showed consistent 100% efficacy against E. coli, with other antibiotics displaying only partial effectiveness. Conclusions: These findings highlight the need for ongoing surveillance of ESBL-producing bacteria and underscore challenges in managing antibiotic resistance due to limited efficacy of last-resort treatments. The unique phenotypical distribution observed could impact local resistance management strategies in hospital settings in the coming years.

9 June 2025 in European Pharmaceutical Journal
Verified
Journal Article
Open access
PDF file
JPJuraj Piestansky
Juraj Piestansky
ZKZuzana Kilianova
Zuzana Kilianova
AOAnna Oleárová
Anna Oleárová
With great pleasure, we present you a special issue of the European Pharmaceutical Journal, which is represented by an abstract collection from the Second Conference of Therapeutic Drug Monitoring-TDM 2025. The conference was organised by the Faculty of Pharmacy of the Comenius University Bratislava, in cooperation with the Section of Clinical Pharmacy of the Slovak Pharmaceutical Society. Indeed, from 11 to 12 April 2025, we were pleased to host at the Faculty of Pharmacy in Bratislava more than 100 participants-clinical pharmacists, analytical chemists, pharmaceutical technologists, toxicologists, and physicians, from Slovakia, the Czech Republic, and Poland. The symposium covered three main topics: (a) Preanalytical and analytical stage of therapeutic drug monitoring, (b) Toxicology and antidoping, and (c) Clinical applications and case studies. In addition to the lectures, three practical workshops were a part of the conference. Two of the practical workshops were dedicated to the analytical methods used in the sample pretreatment and real analysis of biological samples. A special emphasis has been given to the high-resolution tandem mass spectrometry, which is particularly effective in forensics and toxicology due to its unmatched sensitivity, its ability to detect and identify a wide range of substances at low concentrations, and its capacity to handle complex samples with high specificity and precision. With the current progress in both hardware and software, it strongly supports identification of unknowns, quantitation, multi-compound screening, detailed structural information with high throughput, efficiency, and reliable confirmation of results. The last workshop was focused on the practical aspects of the clinical pharmacy in hospital environment. Practical tips, trick, and improvement of clinical skills were trained by the workshop leader Dr. Sharmeen Roy. The main goal of the Second Conference of Therapeutic Drug Monitoring was to bring together all aspects and procedures accompanied with the therapeutic drug monitoring in clinical, toxicological, forensic, and antidoping environment. We hope that such type of conference is an excellent opportunity to enjoy discussion with specialist and share experience with others from different scientific areas and clinical workplaces.